Fig. 4.

Irinotecan and idarubicin do not alter migration of IMR-32 cells after scratch injury or of neurons from cerebellar explants. (a) Representative phase contrast images of IMR-32 cells, 0 and 24 hours after scratch injury depicting gap size in untreated control, irinotecan (10 nM) and nitrendipine (negative control; 10 nM) treated cells. Scale bar = 200 μm. Histogram represents % gap size (mean ± SEM) in control, irinotecan and nitrendipine treated cells after 24 hours of treatment (initial gap width was taken as 100%). The experiment was performed thrice with two wells per condition (n = 3). No statistically significant differences between control and treated cells were seen (p > 0.05, one-way ANOVA with Holm-Sidak post hoc test). (b) Representative phase contrast images of untreated explants (-) and explants treated with idarubicin, irinotecan or nitrendipine (negative control) (all 100 fM) 24 hours after treatment. Histogram shows the number of migrating cells out of cerebellar explants (mean + SD) from control, irinotecan, idarubicin or nitrendipine treated explants at indicated concentrations 24 hours after treatment. The experiment was performed independently four times and at least 12 explants were analyzed in each experiment (n = 4). No statistically significant differences between control and treated explants were seen (p > 0.05, one-way ANOVA with Holm-Sidak post hoc test). Scale bar, 50 μm.